S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire

Disc Medicine Opco (IRON) Stock Forecast, Price & News

$49.00
+0.02 (+0.04%)
(As of 09/21/2023 ET)
Compare
Today's Range
$47.52
$49.50
50-Day Range
$45.00
$55.99
52-Week Range
$11.80
$57.70
Volume
133,571 shs
Average Volume
247,010 shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.78

Disc Medicine Opco MarketRank™ Forecast

Analyst Rating
Buy
3.10 Rating Score
Upside/​Downside
9.8% Upside
$53.78 Price Target
Short Interest
Healthy
2.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Disc Medicine Opco in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$77.79 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.47) to ($3.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.38 out of 5 stars

Medical Sector

908th out of 966 stocks

Pharmaceutical Preparations Industry

427th out of 451 stocks


IRON stock logo

About Disc Medicine Opco (NASDAQ:IRON) Stock

Disc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria. In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.

IRON Price History

IRON Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Disc Medicine: Rare Disease Developer Derisking Itself
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Disc Medicine Inc (IRON)
Disc Medicine Opco (NASDAQ: IRON)
Why Shares of Disc Medicine Opco Climbed This Week
See More Headlines
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine Opco and its competitors with MarketBeat's FREE daily newsletter.

IRON Company Calendar

Last Earnings
8/11/2023
Today
9/21/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IRON
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.78
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+9.8%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

Net Income
$-46,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$10.15 per share

Miscellaneous

Free Float
21,800,000
Market Cap
$1.12 billion
Optionable
Not Optionable
Beta
-0.08
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. John D. Quisel Esq. (Age 52)
    J.D., Ph.D., CEO, Pres, Sec. & Director
    Comp: $750.12k
  • Ms. Joanne Bryce CPA (Age 56)
    Chief Financial Officer
    Comp: $539.32k
  • Mr. Jonathan Yu (Age 42)
    Chief Bus. Officer
    Comp: $539.32k
  • Dr. William Jacob Savage M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $571.95k
  • Dr. Brian MacDonald ChB (Age 63)
    MB, Ph.D., Founder & Chief Innovation Officer
  • Dr. Rahul Khara J.D. (Age 41)
    Pharm.D., Gen. Counsel, Compliance Officer & Sec.
  • Mr. Srikanth Venkatraman Ph.D.
    Sr. VP & Head of Chemistry
  • Ms. Hua Yang Ph.D.
    Sr. VP of Nonclinical Devel.













IRON Stock - Frequently Asked Questions

Should I buy or sell Disc Medicine Opco stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine Opco in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRON shares.
View IRON analyst ratings
or view top-rated stocks.

What is Disc Medicine Opco's stock price forecast for 2023?

10 brokerages have issued 12-month target prices for Disc Medicine Opco's shares. Their IRON share price forecasts range from $30.00 to $75.00. On average, they anticipate the company's stock price to reach $53.78 in the next year. This suggests a possible upside of 9.8% from the stock's current price.
View analysts price targets for IRON
or view top-rated stocks among Wall Street analysts.

How have IRON shares performed in 2023?

Disc Medicine Opco's stock was trading at $17.95 on January 1st, 2023. Since then, IRON shares have increased by 173.0% and is now trading at $49.00.
View the best growth stocks for 2023 here
.

Are investors shorting Disc Medicine Opco?

Disc Medicine Opco saw a decline in short interest in August. As of August 31st, there was short interest totaling 502,000 shares, a decline of 6.2% from the August 15th total of 535,400 shares. Based on an average daily volume of 234,400 shares, the short-interest ratio is currently 2.1 days.
View Disc Medicine Opco's Short Interest
.

When is Disc Medicine Opco's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IRON earnings forecast
.

How were Disc Medicine Opco's earnings last quarter?

Disc Medicine Opco Inc (NASDAQ:IRON) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.12.

What ETFs hold Disc Medicine Opco's stock?

ETFs with the largest weight of Disc Medicine Opco (NASDAQ:IRON) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What is Disc Medicine Opco's stock symbol?

Disc Medicine Opco trades on the NASDAQ under the ticker symbol "IRON."

Who are Disc Medicine Opco's major shareholders?

Disc Medicine Opco's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (6.73%), Perceptive Advisors LLC (3.75%), Citadel Advisors LLC (3.29%), BlackRock Inc. (2.54%), Polar Capital Holdings Plc (2.15%) and Rock Springs Capital Management LP (1.84%). Insiders that own company stock include Brian Richard Macdonald, Holdings A/S Novo, Joanne Bryce, Kevin Bitterman, Venture Fund X LP Atlas and William Jacob Savage.
View institutional ownership trends
.

How do I buy shares of Disc Medicine Opco?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Disc Medicine Opco's stock price today?

One share of IRON stock can currently be purchased for approximately $49.00.

How much money does Disc Medicine Opco make?

Disc Medicine Opco (NASDAQ:IRON) has a market capitalization of $1.12 billion.

How can I contact Disc Medicine Opco?

Disc Medicine Opco's mailing address is 297 Boston Post Road #248, Wayland MA, 01778. The official website for the company is www.discmedicine.com. The company can be reached via phone at 617-401-4400 or via email at ir@geminitherapeutics.com.

This page (NASDAQ:IRON) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -